Patterns of Bisphosphonate Use in the United States in the Treatment of Metastatic Bone Disease
- 1 August 2007
- journal article
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 7 (9), 682-689
- https://doi.org/10.3816/cbc.2007.n.027
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Bisphosphonates for malignancy-related bone disease: current status, future developmentsSupportive Care in Cancer, 2006
- Ibandronic AcidDrugs, 2006
- Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 YearsThe Oncologist, 2005
- Renal Safety of IbandronateThe Oncologist, 2005
- Bisphosphonates in Metastatic Bone Disease: Renal Safety MattersThe Oncologist, 2005
- Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United KingdomClinical Therapeutics, 2005
- Recent developments in bisphosphonates for patients with metastatic breast cancerBMJ, 2005
- Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing RegimensThe Oncologist, 2004
- The role of bisphosphonates in breast and prostate cancers.Endocrine-Related Cancer, 2004
- British Association of Surgical Oncology Guidelines: The management of metastatic bone disease in the United KingdomEuropean Journal of Surgical Oncology, 1999